N-methoxy-N-methyl-amide

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-methoxy-N-methyl-amide
• 英文别名: Methoxy-methyl amide；methoxy(methyl)azanide
• 化学式: C₂H₆NO
• 分子量: 60.0757
• InChiKey: LTKXCIAOFZUMLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  4
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  10.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  异丙基氯化镁 、 methyl thieno[2,3-d]pyrimidine-6-carboxylate 、 N-methoxy-N-methyl-amide 在 氯化铵 、 乙酸乙酯 、 magnesium sulfate 、 silica 、 ethyl acetate n-hexane 作用下， 以 四氢呋喃 为溶剂， 反应 0.5h， 以afforded the title compound as a pale yellow solid (107 mg, 67%)的产率得到N-methoxy-N-methylthieno[2,3-d]pyrimidine-6-carboxamide
  参考文献：
  名称：

  Condensed pyridines and pyrimidines with tie2 (tek) activity

  摘要：

  化合物的式子（I），其中A与其连接的碳原子一起形成一个融合的5元杂环芳基环，其中该杂环芳基环含有1或2个从O，N和S中选择的杂原子，并且含有G的5元环与在式子（I）中被标记为#的桥头碳上的A形成的环在间位连接：G从O，S和NR5中选择；Z从N和CR6中选择；Q1从可选取代的芳基和杂环基中选择，取代基R1到R6如文本中所定义，用于在温血动物如人中产生抗血管生成效应的制备。

  公开号：

  US20050256140A1
• 作为产物：
  描述：

  N-甲基-N-甲氧基胺盐酸盐 在 NH2 radical 作用下， 生成 methanolate 、 methanimine anion 、 N-methoxy-N-methyl-amide
  参考文献：
  名称：

  Base-induced imine-forming 1,2-elimination reactions in the gas phase

  摘要：

  The gas-phase reactivity of CH3NHOCH3 (N,O-dimethylhydroxylamine, DHA) and NH2OCH3 (O-methylhydroxylamine, MHA) toward a series of anionic bases has been studied using the method of Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometry. Both DHA and MHA undergo a competing proton abstraction from and nucleophilic substitution reaction on the nitrogen atom. The competition between these processes is governed by the strength of the base used. Unexpectedly, the nucleophilic attack on the nitrogen atom leading to the substitution of the methoxy group is found to be a relatively facile process. This is especially evident in the substitution reactions with O-methylhydroxylamine, NH2OCH3, where the formation of methoxide ions is much more efficient than in the highly inefficient substitution reactions of dimethyl ether, CH3OCH3. Apparently, substitution reactions on the nitrogen atom do not suffer from a very unfavorable activation barrier which is assumed to hamper nucleophilic substitution reactions on carbon atoms in the gas phase. This seems to be supported by high-level density-functional (DF) calculations which indicate that the nucleophilic substitution reactions on the nitrogen atom proceed via an entropically favored less tight, S(N)1-like transition state. However, in the reactions of N,O-dimethylhydroxylamine, Ch3NHOCH3, the proton abstraction and substitution processes unfavorably compete with a base-induced imine-forming 1,2-elimination. The efficiency of the imine-forming elimination reactions of CH3NHOCH3 can be compared favorably with the efficiency of base-induced alkene-forming 1,2-elimination reactions of corresponding simple ethers such as CH3CH2OC2H5.

  DOI：

  10.1021/jo00061a016

文献信息

• Pyridinyl-1H-pyrazole-1-alkanamides as antiarrhythmic agents
  申请人：Sterling Drug Inc.

  公开号：US04925857A1

  公开（公告）日：1990-05-15

  N-[(alkylamino)alkyl]-4,5-diaryl-1H-pyrazole-1-acetamides, wherein at least one of the aryl substituents is a pyridine, useful for treating cardiac arrhythmias in mammals, are prepared by reacting a lower-alkyl ester of pyrazole-1-acetic acid with an appropriate diamine.

  至少一个芳基取代基为吡啶基的N-[(烷基氨基)烷基]-4,5-二芳基-1H-吡唑-1-乙酰胺类化合物，可用于治疗哺乳动物的心律失常，其制备方法为将吡唑-1-乙酸较低烷基酯与适当的二胺反应。
• Azetidine derivatives, their preparation and pharmaceutical compositions containing them
  申请人：——

  公开号：US20010027193A1

  公开（公告）日：2001-10-04

  Compounds of formula: 1 in which R represents a CR 1 R 2 , C═C(R 5 )SO 2 R 6 or C═C(R 7 )SO 2 alk radical, their preparation and the pharmaceutical compositions containing them.

  公式为1的化合物中，R代表CR1R2、C═C(R5)SO2R6或C═C(R7)SO2烷基，其制备方法以及含有它们的药物组合物。
• Condensed pyridines and pyrimidines with tie2 (tek) activity
  申请人：Luke Arthur Richard William

  公开号：US20050256140A1

  公开（公告）日：2005-11-17

  A compound of the Formula (I), wherein A together with the carbon atoms to which it is attached forms a fused 5-membered heteroaryl ring, wherein said heteroaryl ring contains 1 or 2 heteroatoms selected from O, N and S, and wherein the 5-membered ring containing G is linked to the ring formed by A in the meta position to the bridgehead carbon marked # in Formula (I): G is selected from O, S and NR 5 ; Z is selected from N and CR 6 ; Q 1 is selected from optionally substituted aryl and heteroaryl, and the substituents R 1 to R 6 are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man.

  化合物的式子（I），其中A与其连接的碳原子一起形成一个融合的5元杂环芳基环，其中该杂环芳基环含有1或2个从O，N和S中选择的杂原子，并且含有G的5元环与在式子（I）中被标记为#的桥头碳上的A形成的环在间位连接：G从O，S和NR5中选择；Z从N和CR6中选择；Q1从可选取代的芳基和杂环基中选择，取代基R1到R6如文本中所定义，用于在温血动物如人中产生抗血管生成效应的制备。
• Quinuclidine derivatives processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
  申请人：Guyaux Michel

  公开号：US20050020660A1

  公开（公告）日：2005-01-27

  The invention concerns quinuclidine derivatives of formula I or II wherein the substituents are as defined in the specification, as well as their use as pharmaceuticals. The compounds of the invention_show high affinities for m3 and/or m2 muscarinic receptors and are particularly suited for treating urinary incontinence.

  本发明涉及式I或II的季铵盐衍生物，其中取代基如规范中所定义，以及它们作为药物的用途。本发明的化合物具有高亲和力m3和/或m2胆碱能受体，特别适用于治疗尿失禁。
• Cysteine protease inhibitors
  申请人：Cortech Inc.

  公开号：US06004933A1

  公开（公告）日：1999-12-21

  The present invention relates to cysteine protease inhibitors of the general formula (I): ##STR1## wherein Z is a cysteine protease binding moiety; X and Y are S, O or optionally substituted N; and R.sub.1 is optionally substituted alkyl or aryl.

  本发明涉及一般式（I）的半胱氨酸蛋白酶抑制剂：##STR1## 其中Z是半胱氨酸蛋白酶结合基；X和Y是S，O或可选取代的N；R.sub.1是可选取代的烷基或芳基。